Exabis Library
Welcome to the e-CCO Library!
P371: Concentrations of 6-thioguanine nucleotide correlate with both infliximab and adalimumab levels in patients with inflammatory bowel disease on combination therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P371: Healthcare maintenance in inflammatory bowel disease patients: need for a top down approach
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P371: Outcome of immediate infliximab optimisation based on rapid assessment of serum drug and faecal calprotectin concentrations in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P371: The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P371: Using digital monitoring during the COVID pandemic to streamline outpatient appointments
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P371: Vedolizumab is associated with changes in innate rather than T-cell immunity in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P372: A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis*
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P372: A pilot study: A psychological support service for patients with inflammatory bowel disease (PSSPIBD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P372: Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P372: Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCU
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P372: Endoscopic ultrasonography in the differential diagnosis of Ulcerative colitis and Crohn's disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P372: Neurological symptoms and imaging abnormalities in brain MRI in patients with Crohn’s disease receiving anti-TNFa therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P372: The long term course of patients undergoing ileal pouch-anal anastomosis for ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P373: Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P373: An Unusual Occurrence of Right-sided Colonic Neuroendocrine Carcinoma in Ulcerative Colitis – A case report
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P373: Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P373: Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM